Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 29Terminated 5Recruiting 4Withdrawn 2Suspended 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 12Leukemia, Myeloid, Acute 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Myelomonocytic, Chronic 6Graft vs Host Disease 5Myeloproliferative Disorders 4Hematologic Neoplasms 4Leukemia 3Hodgkin Disease 3Primary Myelofibrosis 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Monocytic, Acute 2Leukemia, Lymphoid 2Leukemia, Biphenotypic, Acute 2Anemia, Refractory, with Excess of Blasts 2beta-Thalassemia 1Thrombocythemia, Essential 1Thalassemia 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Osteosarcoma 1Neuroblastoma 1Myelodysplastic-Myeloproliferative Diseases 1Myasthenia Gravis 1Multiple Myeloma 1Leukemia, Myeloid 1

Interventions

Cyclophosphamide 22fludarabine 20venetoclax 8Whole-Body Irradiation 8Mycophenolic Acid 8Standard of Care 6Mesna 6Melphalan 6Azacitidine 6fludarabine phosphate 5Sirolimus 5thymoglobulin 4Thiotepa 4Tacrolimus 4Surveys and Questionnaires 4Specimen Handling 4Filgrastim 4Cytarabine 4entrectinib 3daratumumab 3cobimetinib 3alectinib 3Vemurafenib 3Rituximab 3Practice Guidelines as Topic 3Palliative Care 3Granulocyte Colony-Stimulating Factor 3Busulfan 3Bortezomib 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Hematologic Neoplasms × Tacrolimus × Clear all
NCT07359859 2026-05-27

A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
40 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

NCT03670966 2026-05-04

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
30 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06807606 2026-04-28

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Recruiting
35 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT06926595 2026-04-03

GVHD-PTCy

Milton S. Hershey Medical Center

Phase 2 Recruiting
41 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡